Skip to main content

Multiple Sclerosis Discovery Forum

Inspiring Connections

Utility Navigation

Feedback
Newsletter
RSS
Twitter

User Top Menu

Welcome, guest
Log In
Join
Why Join?

Search form

Search

About Us
- Overview
- Who We Are
- Contact
- Fan Mail
- How to Cite
News & Future Directions
Papers
Forums
- Discussions
- Webinars
Professional Resources
Research Resources
Click Here to Support MSDF

You are here

Most Viewed

3 Blockbuster Drugs Losing Patent Protection in 2013's Final Months
Rituximab and multiple sclerosis.
Raxone®/Catena® (idebenone)
Santhera and NIH collaborate to evaluate Catena® in primary progressive multiple sclerosis
Neuromyelitis optica: Evaluation of 871 attacks and 1153 treatment courses.
Once-daily AUBAGIO® delayed onset of clinically definite multiple sclerosis (MS) in TOPIC study
Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
Complex antibody profiling to predict clinical outcome in childhood ADS.
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
Architecture of human mTOR complex 1.
Glatiramer Acetate administration does not reduce damage after cerebral ischemia in mice.
Santhera's Phase III program with Catena®/Raxone® in Duchenne muscular dystrophy on track to deliver pivotal data early in 2Q 2014
Serum from interferon-β-1b-treated patients with early multiple sclerosis stabilizes the blood-brain barrier in vitro.
Power estimation for non-standardized multisite studies.
Genzyme’s once-daily, oral AUBAGIO® approved in Australia for treatment of relapsing multiple sclerosis
A G protein-coupled receptor is essential for Schwann cells to initiate myelination.
ARESTIN®
Interferon β-1b directly modulates human neural stem/progenitor cell fate.
Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders.
Dietary Fatty Acids Directly Impact Central Nervous System Autoimmunity via the Small Intestine.
Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study.
Oracle Cladribine in Early Multiple Sclerisis (MS) (ORACLE MS)
Receptos to initiate Phase 3 trial of RPC1063 in relapsing multiple sclerosis
Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy.
Multiple Sclerosis and Pregnancy: Current Considerations.

Pages

« first
‹ previous
…
101
102
103
104
105
106
107
108
109
…
next ›
last »

MSDF Footer

Copyright © 2014 MGH and ACP

Privacy
Terms of Use
How to Cite
FAQ/Help
Site Map
Support Us
Feedback
Image Credits

All site content, except where otherwise noted, is licensed under a Creative Commons BY license. Please let us know where and how you use MSDF material.

Content By

Software By